ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Overexpression of histidine decarboxylase promotes cancer cell apoptosis and migration in HN5 cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to assess the expression of histidine decarboxylase (HDC) in oral squamous cell carcinoma (OSCC) and investigate its functional role in patient prognosis as well as in apoptosis and migration of OSCC cells. A total of 58 formalin-fixed, paraffin-embedded OSCC tissue samples were examined to analyze the correlation between HDC expression levels and overall patient survival. Further, the effects of HDC modulation were studied in vitro using the HN5 cell line. Histidine, phorbol 12-myristate 13-acetate (PMA), quercetin, and their combinations with histidine were used to alter HDC expression level. The resulting changes in cell proliferation, apoptosis, migration, the expression of matrix metalloproteinases (MMP2, MMP7, MMP9), and histamine receptors were assessed using the MTT assay, flow cytometry, wound healing assay, and RT-qPCR. Immunohistochemistry data showed that patients with low HDC expression had significantly poorer overall survival compared to those with high HDC expression. In vitro findings showed that combined treatment of histidine and PMA significantly increased HDC expression level beyond the levels observed with each agent alone. Co-treatment of histidine + PMA also caused a notable increase in apoptosis. However, it simultaneously promoted cell migration and upregulated the expression of MMP2, MMP7, and MMP9. These results suggest that while HDC overexpression may contribute to improved prognosis in OSCC by promoting apoptosis, its concurrent role in enhancing tumor cell migration presents a paradox that requires further investigation.
Indexed as
Identifiers
41345302What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.